RAPT Therapeutics, Inc.
RAPT
$32.01
-$0.32-0.99%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.79% | 7.55% | -6.64% | 24.11% | -6.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.11% | -33.40% | -40.76% | 63.97% | -41.66% |
| Operating Income | 2.11% | 33.40% | 40.76% | -63.97% | 41.66% |
| Income Before Tax | 4.62% | 36.22% | 43.76% | -72.46% | 41.25% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 4.62% | 36.22% | 43.76% | -72.46% | 41.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.62% | 36.22% | 43.76% | -72.46% | 41.25% |
| EBIT | 2.11% | 33.40% | 40.76% | -63.97% | 41.66% |
| EBITDA | 1.67% | 33.48% | 40.96% | -64.70% | 41.98% |
| EPS Basic | 82.80% | 88.50% | 89.92% | -41.79% | 42.07% |
| Normalized Basic EPS | 82.80% | 88.50% | 89.84% | -37.74% | 42.07% |
| EPS Diluted | 82.80% | 88.50% | 89.92% | -41.79% | 42.07% |
| Normalized Diluted EPS | 82.80% | 88.50% | 89.84% | -37.74% | 42.07% |
| Average Basic Shares Outstanding | 454.47% | 454.72% | 457.69% | 21.63% | 1.42% |
| Average Diluted Shares Outstanding | 454.47% | 454.72% | 457.69% | 21.63% | 1.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |